KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Asset Writedowns and Impairment (2018 - 2024)

AbbVie (ABBV) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with $4.5 billion as the latest value for Q4 2024.

  • On a quarterly basis, Asset Writedowns and Impairment rose 218.58% to $4.5 billion in Q4 2024 year-over-year; TTM through Dec 2025 was $4.5 billion, a 0.0% change, with the full-year FY2025 number at $847.0 million, down 81.08% from a year prior.
  • Asset Writedowns and Impairment was $4.5 billion for Q4 2024 at AbbVie, up from $1.4 billion in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $4.5 billion in Q4 2024 to a low of $80.0 million in Q2 2023.
  • A 3-year average of $1.6 billion and a median of $1.1 billion in 2022 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 174.55% in 2023, then skyrocketed 218.58% in 2024.
  • AbbVie's Asset Writedowns and Impairment stood at $770.0 million in 2022, then soared by 82.47% to $1.4 billion in 2023, then surged by 218.58% to $4.5 billion in 2024.
  • Per Business Quant, the three most recent readings for ABBV's Asset Writedowns and Impairment are $4.5 billion (Q4 2024), $1.4 billion (Q4 2023), and $2.1 billion (Q3 2023).